



CONTACT: Kenneth W. Locke, Ph.D.
Chief Scientific Officer
Lithera, Inc.
9191 Towne Centre Drive
San Diego, CA 92122
Phone: 858-750-1008
E-mail: klocke@lithera.com

FOR IMMEDIATE RELEASE

Lithera to Present at Three Upcoming Conferences

SAN DIEGO, Calif. – October 5, 2010 – Lithera, Inc. today announced that it will present key clinical data and progress updates on the development of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. Lithera will present at the following three conferences:

- 2010 Joint Annual Meeting of the American Society for Dermatologic Surgery/
American Society of Cosmetic Dermatology and Aesthetic Surgery on Friday,
October 22, 2010, at 2:19 PM at the Hyatt Regency Chicago on the Riverwalk

Dr. Adam M. Rotunda (Assistant Clinical Professor of Dermatology, David Geffen School of Medicine, UCLA) will deliver a presentation entitled “Evaluation of LIPO-102 (Salmeterol Xinafoate (SX) + Fluticasone Propionate (FP) for Injection) for the Reduction of Abdominal Subcutaneous Fat”. Clinical data will be presented showing that LIPO-102 produces significant reductions in abdominal circumference and volume.

- Oppenheimer 21st Annual Healthcare Conference on Tuesday, November 2, 2010,
at 11:25 AM in the Louis XVI Room at The Waldorf-Astoria in New York City

Dr. John D. Dobak (Chief Executive Officer, Lithera, Inc.) will present a progress update on the development of LIPO-102 as well as late-breaking clinical study results.

- Windhover’s Therapeutic Area Partnerships on Wednesday, November 3, 2010, at 2:30 PM at the Westin Copley Place in Boston

LIPO-102 was selected as one of the Top 10 Projects to Watch in our Hot Space by Windhover Information and the publishers of *In Vivo* and *Startup*. Dr. John D. Dobak will present a progress update on the development of LIPO-102 as well as late-breaking clinical study results.

About LIPO-102

LIPO-102 is being developed as a first-in-class injectable drug product designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty). Using FDA-registered drugs approved for use in other indications, LIPO-102 targets and stimulates natural fat tissue metabolism to achieve non-ablative, non-surgical fat tissue reduction in specific locations. LIPO-102 is currently under development for the treatment of symptomatic exophthalmos (protrusion of the eye from the orbit) associated with thyroid-related eye disease (the thyroid condition is also known as Graves’ Disease) and the reduction of abdominal adiposity.

About Lithera

Lithera is a clinical stage company developing pharmaceutical and biomedical products addressing both medical and lifestyle indications in ophthalmology and aesthetic medicine. Our lead product candidate (LIPO-102) is a novel injectable pharmaceutical product designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty). Founded in 2007, the Company has assembled an exceptional team of senior executives, employees and advisors and has been financed by top-tier venture capital firms. For more information on Lithera, Inc., please visit www.lithera.com.

Lithera, LIPO-102 and the Lithera logo are trademarks or registered trademarks of Lithera, Inc. Other names and brands may be claimed as the property of others.